DGI-038 Gemtuzumab Ozogamicin as Salvage Treatment in Children with Acute Myeloid Leukaemia Relapse: A Retrospective Study
نویسندگان
چکیده
منابع مشابه
Gemtuzumab ozogamicin in the treatment of adult acute myeloid leukemia
Gemtuzumab ozogamicin (GO) is a humanized anti-CD33 monoclonal antibody conjugated to a derivative of an antitumor antibiotic, calicheamicin. GO was approved for the treatment of relapsed acute myeloid leukemia (AML) in the United States (US) in 2000. However, GO was withdrawn from the US market in June 2010, because a large-scale clinical trial failed to show additive or synergistic effects wi...
متن کاملThe role of gemtuzumab ozogamicin in acute leukaemia therapy.
Gemtuzumab ozogamicin (GO) is an immunoconjugate that binds to CD33 on the surface of acute myeloid leukaemia (AML) blasts and, after internalisation, releases a cytotoxic drug, calicheamicin. GO is approved by the US Food and Drug Administration for the treatment of CD33-positive AML at first relapse in patients 60 years and older who are not candidates for other cytotoxic therapy. GO as a sin...
متن کاملLow dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.
Introduction. Acute myeloid leukemia (AML) in the elderly presents with peculiar characteristics, and current conventional approaches achieve only poor results, especially in relapsed patients. In particular, intensified regimens do not offer advantages in terms of clinical response, and even cause significant toxicity. Thus, alternative strategies able to combine efficacy and a low profile of ...
متن کاملApproval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
PURPOSE Gemtuzumab ozogamicin (Mylotarg; Wyeth Laboratories, Philadelphia, PA) consists of a semisynthetic derivative of calicheamicin, a cytotoxic antibiotic linked to a recombinant monoclonal antibody directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). In this study, we review the preclinical and clinical profiles of this immun...
متن کاملImproved outcome after relapse in children with acute myeloid leukaemia.
In the Nordic Society for Paediatric Haematology and Oncology paediatric study acute myeloid leukaemia (AML) 93, event-free survival was 50% and overall survival was 66%, indicating that many patients were cured following relapse. Factors influencing outcome in children with relapsed AML were investigated. The study included all 146 children in the Nordic countries diagnosed with AML between 19...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Hospital Pharmacy
سال: 2013
ISSN: 2047-9956,2047-9964
DOI: 10.1136/ejhpharm-2013-000276.304